Integration Has Moved From Theory to a Health System Test

The future of infectious disease elimination is increasingly tied to routine care rather than stand-alone campaigns. A scoping review published in BMJ Open examined how treatment and surveillance functions for diseases targeted for elimination or eradication have been integrated into health systems across low- and middle-income countries, and the evidence points to a pattern that is broader than any single pathogen or program model. Across 45 studies from 23 countries and 20 diseases, integration consistently looked less like a narrow program tweak and more like a structural shift in how health services absorb responsibility for case finding, treatment delivery, reporting, and oversight.

The review followed Joanna Briggs Institute guidance and PRISMA-ScR standards, then mapped evidence from 2010 through 2024. Its scope matters because the elimination agenda has long depended on vertical, donor-driven infrastructure, while current funding pressures and policy priorities have pushed countries toward ownership and sustainability. Within that transition, the central question is not whether integration is desirable in principle. It is whether health systems can absorb new disease-specific tasks without losing reach, accountability, or surveillance quality.

Task Shifting, Community Platforms, and New Administrative Burdens

Integration was most often operationalized through task shifting to primary healthcare providers, expanded roles for community health workers, and new responsibilities for district and national health authorities. In practical terms, elimination programs were no longer isolated units running parallel to the system; they were being folded into existing service delivery points and governance layers. That shift can widen access, especially where specialty services are thin, but it also redistributes work to staff and managers who may already be carrying full clinical loads.

A single sentence captures the operational tension: integration often succeeds by moving work, not removing it.

Clinical and public health workers were asked to take on functions that previously sat outside routine care. Primary care teams became responsible for more treatment activity. Community health workers were pulled into surveillance and community-based engagement. District and national authorities were given additional planning, reporting, and coordination duties. Those changes align with how elimination campaigns evolve when they move from intensive external support toward domestic stewardship, but they also create new demands on training, supervision, procurement, and data flow.

The review identified a recurring facilitator that cut across settings and diseases: a health systems strengthening approach paired with strong government ownership. In other words, integration worked best when it was not treated as an isolated intervention. When ministries, districts, frontline providers, and partners were aligned around a broader service-delivery strategy, integration had a better chance of becoming routine practice rather than a temporary overlay. In settings where leadership was fragmented, the transition appears to have been more difficult to sustain.

Surveillance and Cost Data Lag Behind Treatment Integration

Surveillance emerged as the weakest part of the evidence base. Most included studies described treatment integration more clearly than surveillance integration, leaving a major gap in understanding how case detection, notification, data quality, and response systems behave once elimination work is embedded in routine services. Surveillance is not a passive add-on. It is the mechanism that tells health systems whether elimination remains intact, where transmission persists, and when response capacity needs to be reactivated.

The limited surveillance evidence leaves an operational blind spot. Without durable reporting and feedback loops, elimination gains can be difficult to verify and even harder to protect.

Economic data were also sparse. Some studies described a familiar funding trajectory: donor-supported start-up phases followed by longer-term absorption by governments. That model may help programs launch, but it does not by itself establish whether integration is affordable at scale, how much of the cost shifts to domestic budgets, or which components create the largest recurring burden. The review found only limited evidence on costs, and that absence is consequential because sustainability is ultimately a financial as well as a technical problem.

Several barriers appeared repeatedly. Supply chain problems interfered with service continuity. Roles were sometimes unclear, creating confusion over who should do what once programs were integrated. Partner coordination was often weak, which can fragment decision-making and produce parallel reporting or duplicated support. These are familiar health system constraints, but they become more visible when elimination programs are no longer buffered by vertical structures. Once responsibilities are spread across multiple levels of care, small failures in logistics or governance can ripple through the system quickly.

What the Evidence Suggests for Future Elimination Strategy

The included studies were not methodologically uniform, and the review explicitly notes that the research designs reflected varied disciplinary perspectives. That heterogeneity limits direct comparison, but it also reflects the real-world complexity of integration. Health systems do not absorb infectious disease programs in a standardized way. They adapt according to workforce structure, financing, governance, and disease burden, which is why a multi-disease scoping approach was well suited to this question.

The central clinical and policy message is straightforward: integration should be treated as a health system change process from the outset. Planning needs to begin early, before donor support tapers. Country leadership has to be visible and durable. Coordination with external partners must be tighter if roles are going to be redistributed without confusion. Broader engagement across the health system is essential because treatment and surveillance are linked to supply chains, data systems, frontline staffing, referral pathways, and administrative oversight.

From a bedside and population-health perspective, this matters because elimination only holds when routine systems can recognize disease, deliver treatment, and document response without relying on exceptional infrastructure. Integration can improve continuity and local ownership, but it can also expose weak points that vertical programs once concealed. The review does not offer a single model that fits every disease or setting. It does show that sustainability depends on whether integration is built as a core function of the health system rather than a temporary project layered on top of it.

The largest unanswered gaps remain concrete: how surveillance integration performs over time, what it costs to maintain, and which governance arrangements best protect disease gains once external funding recedes.


Reporting by Dr. A.R. Athira, MBBS for Medicine World Foundation, with additional data provided by BMJ Open.